Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome

Creative Commons License

Ozcan O. U., Ustun E. E., GÜLEÇ H. S., GEREDE ULUDAĞ D. M., Goksuluk H., Vurgun V. K., ...More

CARDIOLOGY JOURNAL, vol.22, no.3, pp.323-329, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.5603/cj.a2014.0101
  • Journal Name: CARDIOLOGY JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.323-329
  • Keywords: angiotensin converting enzyme inhibitor, coronary artery disease, metabolic syndrome, percutaneous coronary intervention, periprocedural myocardial infarction, CREATINE KINASE-MB, INTRACORONARY ENALAPRILAT, CARDIOVASCULAR EVENTS, MORTALITY, DISEASE, IMPACT, TRIAL
  • Ankara University Affiliated: Yes

Abstract

Background: Metabolic syndrome (MetS) has been reported as a risk factor for cardiovascular events. The aim of the present study is to investigate the association between chronic angiotensin-converting enzyme inhibitors (ACE-I) therapy and the rate of periprocedural myocardial infarction (PMI) after elective coronary stenting among patients with MetS.